Toshifumi Hoki

[Arndt Vogel @ArndtVogel]

🔥Excellent news: Pivotal phase III IMbrave050 study is positive: The first positive adjuvant trial in #HCC🔥
👉Atezolizumab + Avastin improves RFS in pts at high risk of recurrence following surgery
@myESMO @OncoAlert @EASLedu #livertwitter

[Toshifumi Hoki @dkmlv1]

@BeKaterInTheSky Congrats, Bess!

[The Ito Lab @lab_ito]

I'd like to thank DOD Lung Cancer Research Program for supporting our research. I had a great pleasure working at VA hosp as a resident and staff surgeon before. I hope our work will help improve care for veterans. @wwp @VeteransHealth
https://t.co/oPIjlBoBik

[ひろゆき @hirox246]

「森友」文書不開示は違法。
国が記録を意図的に不開示にした上で、廃棄を進める違法行為があったとして３３万円の賠償を大阪高裁が命じた。
国民として誰でも訴訟出来るので、同じ訴状を近くの裁判所に出すと誰でも33万円貰えるって事だよね？
新たな給付金。
https://t.co/58qtrhooOt

[Toshifumi Hoki @dkmlv1]

@tachibanat 早く回復されてください．

[丸山 穂高 @maruyamahodaka]

本会議終了後、視察で渋谷へ。LUUP乗ってきた！公道でノーヘルですが何か？ヒャッハー！
電動シェアキックボード事故も報道される中で、事業社さんの苦労も聞きつつ、主意書作成中です。百聞は”一験”に如かずですね。会期末までに質問主意書仕上げて政府に出します。

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models @lab_ito @KunleOdunsiMD https://t.co/vRpID5GUEA

[The Ito Lab @lab_ito]

Glad to share our work on the mechanism underlying the generation of tumor-specific #CD8 #Tcells by #neoantigen #vaccination, and the utility of #CX3CR1 as a circulating #biomarker.
#CD40, #CD80, #CD86, #cDC1
https://t.co/eMSfQe1V9f

[Toshifumi Hoki @dkmlv1]

IFNγ signaling paves the way for effective checkpoint blockade https://t.co/UUQfeYgeIt

[The Ito Lab @lab_ito]

Any role of #cDC1s in adoptive #Immunotherapy? Glad to see our new paper @J_Immunol. A BIG thank you to everyone involved @RoswellPark and awesome collaborators. https://t.co/itUlgK1lSp

[ACIR @ACIR_org]

SPOTLIGHT: CX3CR1-CD8+ T cells are critical in antitumor efficacy, but functionally suppressed in the tumor microenvironment @RoswellPark Originally published in @JCI_insight To read our summary click https://t.co/oFm1eWaIKH and scroll all the way down.

[The Ito Lab @lab_ito]

Very nice to see our paper published in JCI insight. Congrats on Drs. Yamauchi, Hoki and Oba. I appreciated help by awesome collaborators.

[Roswell Park @RoswellPark]

Dr. Fumito Ito will share results today of a clinical trial assessing a biomarker as a way to predict response to therapies that target the checkpoint protein PD-1. Dr. Ito's online session takes place at 9:20am EDT. #AACR20 https://t.co/bLHXFG28jm

[Toshifumi Hoki @dkmlv1]

@IHayato 現金払いへの執着

[じょにぃ｜日本に帰ってきました @iam__jonny]

こんにちは！
この度、投資初心者向けセミナーで講演することになりましたー☺️

日時 8月8日（土）14時
場所 ワテラスコモンホール（お茶の水駅近く）
定員 50名
参加費 無料
※詳細はURLからご確認ください

定員の数に限りがあって申し訳ないです🙇‍♂️

#じょにぃちゃんねる

https://t.co/lckeWiVl4Q

[Toshifumi Hoki @dkmlv1]

@tachibanat こういう報道もう飽きた．メディアもうちょっと違うところに力を使って

[Toshifumi Hoki @dkmlv1]

watched

[Toshifumi Hoki @dkmlv1]

better that I thought

[Toshifumi Hoki @dkmlv1]

movie marathon for this weekend have just started!